A detailed history of Russell Investments Group, Ltd. transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 26,606 shares of ITOS stock, worth $193,159. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,606
Previous 1,033 2475.61%
Holding current value
$193,159
Previous $15,000 1706.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.09 - $17.97 $258,031 - $459,546
25,573 Added 2475.61%
26,606 $271,000
Q2 2024

Aug 08, 2024

SELL
$10.33 - $18.09 $393,552 - $689,192
-38,098 Reduced 97.36%
1,033 $15,000
Q1 2024

May 08, 2024

SELL
$9.89 - $13.64 $3,728 - $5,142
-377 Reduced 0.95%
39,131 $533,000
Q4 2023

Feb 05, 2024

BUY
$8.57 - $11.06 $135,037 - $174,272
15,757 Added 66.34%
39,508 $432,000
Q3 2023

Nov 13, 2023

SELL
$10.95 - $14.6 $14,289 - $19,053
-1,305 Reduced 5.21%
23,751 $260,000
Q2 2023

Aug 10, 2023

BUY
$12.93 - $18.05 $1,874 - $2,617
145 Added 0.58%
25,056 $331,000
Q1 2023

May 09, 2023

SELL
$13.02 - $22.62 $3,658 - $6,356
-281 Reduced 1.12%
24,911 $339,000
Q4 2022

Feb 08, 2023

SELL
$17.77 - $21.6 $122,613 - $149,040
-6,900 Reduced 21.5%
25,192 $491,000
Q3 2022

Nov 04, 2022

SELL
$18.6 - $27.25 $154,528 - $226,393
-8,308 Reduced 20.56%
32,092 $609,000
Q2 2022

Jul 29, 2022

BUY
$16.57 - $35.1 $391,052 - $828,360
23,600 Added 140.48%
40,400 $832,000
Q1 2022

May 05, 2022

BUY
$31.92 - $47.45 $395,808 - $588,380
12,400 Added 281.82%
16,800 $540,000
Q4 2021

Jan 21, 2022

BUY
$26.23 - $47.86 $115,412 - $210,584
4,400 New
4,400 $204,000
Q3 2021

Nov 08, 2021

SELL
$23.91 - $29.58 $320,370 - $396,342
-13,399 Closed
0 $0
Q2 2021

Aug 04, 2021

BUY
$17.9 - $36.1 $140,855 - $284,070
7,869 Added 142.3%
13,399 $343,000
Q1 2021

May 10, 2021

BUY
$30.86 - $44.2 $170,655 - $244,426
5,530 New
5,530 $189,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $258M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.